Eisai Inc. Release: Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer

CHICAGO--(BUSINESS WIRE)--Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai’s eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician’s Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

Back to news